Clinical Trials
Sunday, April 8th, 2012
A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy Crc.ahajournals.org: Feb. 28, 2012. Abstract Background—Cardiac biomarkers are strong predictors of adverse outcomes in several patient populations. We evaluated the prevalence of elevated troponin I and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and their association to cardiovascular events in atrial fibrillation (AF) patients in the Randomized Evaluation […]
Clinical Trials
Thursday, March 29th, 2012
Archinte.ama-assn.org: Shikhar Agarwal, MD, MPH, CPH; Rory Hachamovitch, MD, MS; Venu Menon, MD , March 26, 2012. Background Although several new antithrombotic agents have been developed for stroke prevention in patients with nonvalvular atrial fibrillation (AF), many patients will continue to be treated with warfarin worldwide. We performed a meta-analysis of safety and efficacy outcomes in patients with […]
Clinical Trials
Thursday, March 29th, 2012
Medicalxpress.com: March 23, 2012. In 2011, the National Institute of Neurological Disorders and Stroke (NINDS) convened the Stroke Progress Review Group (SPRG) to conduct a final 10-year review of the state of stroke research. The goal is to set priorities and shape future NINDS programs and policies. While SPRG found much available data for maximizing stroke […]
Clinical Trials
Thursday, March 29th, 2012
Stroke.ahajournals.org: Alex Pollock, PhD; Christine Hazelton, BSc(Hons); Clair A. Henderson, MSc; Jayne Angilley, BSc; Balijean Dhillon, FRCPS(Glasg); Peter Langhorne, FRCP; Katrina Livingstone, BSc(Hons); Frank A. Munro, BSc; Heather Orr, BSc; Fiona Rowe, PhD; Uma Shahani, PhD., March 8, 2012. An estimated 20% to 57% of people have visual field defects after stroke, affecting function, quality […]
Clinical Trials
Thursday, March 29th, 2012
Stroke.ahajournals.org: Bernd Kallmünzer, MD*; Lorenz Breuer, MD*; Christiane Hering, MD; Dorette Raaz-Schrauder, MD; Rainer Kollmar, MD; Hagen B. Huttner, MD; Stefan Schwab, MD; Martin Köhrmann, MD., Feb. 2, 2012. Background and Purpose—Anticoagulation is a highly effective secondary prevention in patients with cardioembolic stroke and atrial fibrillation/flutter (AF). However, the condition remains underdiagnosed, because paroxysmal AF may […]
Clinical Trials
Thursday, March 29th, 2012
The National Institute of Neurological Disorders and Stroke (NINDS) Stroke Common Data Element (CDE) Project Stroke.ahajournals.org: Jeffrey L. Saver, MD; Steven Warach, MD, PhD; Scott Janis, PhD; Joanne Odenkirchen, MPH; Kyra Becker, MD; Oscar Benavente, MD; Joseph Broderick, MD; Alexander W. Dromerick, MD; Pamela Duncan, PhD; Mitchell S.V. Elkind, MD; Karen Johnston, MD; Chelsea S. Kidwell, […]
Clinical Trials
Thursday, March 22nd, 2012
The New England Journal of Medicine: March 22, 2012. BACKGROUND Intravenous alteplase is the only approved treatment for acute ischemic stroke. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, is an alternative thrombolytic agent. METHODS In this phase 2B trial, we randomly assigned 75 patients to receive alteplase (0.9 mg per kilogram of body weight) or […]
Clinical Trials
Thursday, March 22nd, 2012
Bmj.com: March 20, 2012. A major phase III clinical trial of mild hypothermia to treat stroke patients by cooling the brain will be launched later this year after the consortium involved secured funding of some €11m (£9.2m; $14.5m) from the European Commission’s research programme. Read More
Clinical Trials
Thursday, March 22nd, 2012
Stroke.ahajournals.org: March 15, 2012. Choice of Primary Outcome Measure Abstract Background and Purpose—The diversity of available outcome measures for acute stroke trials is challenging and implies that the scales may be imperfect. To assist researchers planning trials and to aid interpretation, this article reviews and makes recommendations on the available choices of scales. The aim is […]
Clinical Trials
Thursday, March 22nd, 2012
Stroke.ahajournals.org: March 15, 2012. Abstract Common outcome scales in acute stroke trials are ordered categorical or pseudocontinuous in structure but most have been analyzed as binary measures. The use of fixed dichotomous analysis of ordered categorical outcomes after stroke (such as the modified Rankin Scale) is rarely the most statistically efficient approach and usually requires a […]
